KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Accounts Payables (2016 - 2025)

Historic Accounts Payables for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to $5.0 billion.

  • Pfizer's Accounts Payables fell 545.73% to $5.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $5.0 billion, marking a year-over-year decrease of 545.73%. This contributed to the annual value of $5.6 billion for FY2024, which is 1605.07% down from last year.
  • Per Pfizer's latest filing, its Accounts Payables stood at $5.0 billion for Q3 2025, which was down 545.73% from $5.2 billion recorded in Q2 2025.
  • In the past 5 years, Pfizer's Accounts Payables ranged from a high of $6.8 billion in Q4 2022 and a low of $4.1 billion during Q2 2021
  • In the last 5 years, Pfizer's Accounts Payables had a median value of $5.5 billion in 2022 and averaged $5.5 billion.
  • Its Accounts Payables has fluctuated over the past 5 years, first soared by 4347.12% in 2022, then crashed by 1605.07% in 2024.
  • Pfizer's Accounts Payables (Quarter) stood at $5.6 billion in 2021, then rose by 22.07% to $6.8 billion in 2022, then decreased by 1.45% to $6.7 billion in 2023, then dropped by 16.05% to $5.6 billion in 2024, then decreased by 10.81% to $5.0 billion in 2025.
  • Its last three reported values are $5.0 billion in Q3 2025, $5.2 billion for Q2 2025, and $5.2 billion during Q1 2025.